In UK, Actemra was authorised for use in April this year, not sure it’s had any negative impact on GCA patients per se.
But as the drug is normally only authorised for a limited number if GCA patients for a year* over here, unlike the US , it’s a bit difficult to know…but don’t think it’s use for Rheumatoid Arthritis patients (for whom there seems to be no restriction) has been affected.
It has actually been used for at least a year for ICU patients and has been licensed for RA for several years where it is used a lot more than for GCA. As piglette says - Genentech are probably laughing all the way to the bank!
It will probably encourage more trials using biosimilars - biologic drugs that work on IL-6, there are severa in the pipeline.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.